—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Royalty Pharma Plc (RPRX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for RPRX, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.38 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How RPRX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.38 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Royalty Pharma Plc moved 0.38% on average · correlation 0.15 · higher than 38% of US names
  • Beta, last 3 months 0.64 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.74% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.11% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against RPRX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Royalty Pharma Plc

RPRX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Royalty Pharma buys royalty streams from biopharmaceutical companies and helps fund research programmes in exchange for future royalty income. Its holdings span royalties on marketed therapies and drug candidates still in development, covering areas such as rare disease, oncology, neuroscience, infectious disease, haematology and diabetes. It also backs research collaborations, including funding for an investigational autoimmune treatment, without developing or selling drugs itself.
Where it sits in the stack
Royalty Pharma has no seat in our AI-focused Rubin index; within our wider universe it sits in the Healthcare sector, as a royalty aggregator rather than a therapeutics developer.
Who it is priced against
The diary has not assigned Royalty Pharma a peer group; the comparison the market draws is with DRI Healthcare, another buyer of pharmaceutical royalty streams.
Why Closelooknet tracks it
Royalty Pharma is a Russell 1000 constituent; it carries no Closelooknet score yet and has not appeared in any diary edition or quote.
What the diary watches
Whether new royalty purchases and research funding deals, such as the autoimmune programme it backs, keep replenishing the portfolio as older royalties mature and expire.

Royalty Pharma Plc (RPRX) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 1.59%, quarterly · last 0.24 USD on 2026-08-14

Dividends and capital return

What RPRX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.93 USD per share · a 1.59% yield on the 2026-09-25 close 4 distributions, paid quarterly 2026-09-25
  • Change on the year +6.3% against the prior twelve months prior twelve months 0.87 USD per share
  • Last distribution 0.24 USD per share as the price series records it, within days of the ex-date 2026-08-14
  • By calendar year 2023: 0.20 USD (partial) · 2024: 0.84 USD · 2025: 0.88 USD · 2026: 0.71 USD to date first distribution recorded in the three-year window: 2023-11-16

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Royalty Pharma Plc (RPRX)?

Royalty Pharma Plc trades as RPRX on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is RPRX in a Closelooknet index?

Not currently — Royalty Pharma Plc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does RPRX trade against its moving averages?

Pullback inside an uptrend stack: Trades -2% vs the 50-day and +15.4% vs the 200-day average, 9.6% below the 52-week high and +70.7% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Royalty Pharma Plc trade when bond yields rise?

Over the past year Royalty Pharma Plc had a beta of 0.38 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 38% of US names. On the 10 sessions in which long bonds fell most it moved −0.74% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Royalty Pharma Plc do?

Royalty Pharma buys royalty streams from biopharmaceutical companies and helps fund research programmes in exchange for future royalty income. Its holdings span royalties on marketed therapies and drug candidates still in development, covering areas such as rare disease, oncology, neuroscience, infectious disease, haematology and diabetes. It also backs research collaborations, including funding for an investigational autoimmune treatment, without developing or selling drugs itself. The diary has not assigned Royalty Pharma a peer group; the comparison the market draws is with DRI Healthcare, another buyer of pharmaceutical royalty streams.

Where does Royalty Pharma Plc sit in the AI build-out?

Royalty Pharma has no seat in our AI-focused Rubin index; within our wider universe it sits in the Healthcare sector, as a royalty aggregator rather than a therapeutics developer. Royalty Pharma is a Russell 1000 constituent; it carries no Closelooknet score yet and has not appeared in any diary edition or quote.

Does Royalty Pharma Plc pay a dividend?

Royalty Pharma Plc has paid 0.93 USD per share over the last twelve months, paid quarterly, a trailing yield of 1.59% on the 2026-09-25 close; the last distribution recorded in the price series was 0.24 USD on 2026-08-14. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for RPRX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.